The US FDA has scheduled a Joint Meeting of the Drug Safety and Risk Management (DSRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The Committees will discuss the results of post-marketing studies evaluating the misuse and/or abuse of reformulated OXYCONTIN (oxycodone hydrochloride) extended-release tablets, supplemental new drug application (sNDA) 022272, manufactured by Purdue Pharma L.P. The committees will discuss whether these studies have demonstrated that the reformulated OXYCONTIN product has had a meaningful impact on abuse of OXYCONTIN.

See the FDA Announcement